Torsdag 26 December | 16:36:05 Europe / Stockholm

Kalender

Tid*
2026-03-05 06:00 Bokslutskommuniké 2025
2025-11-26 06:00 Kvartalsrapport 2025-Q3
2025-09-17 06:00 Kvartalsrapport 2025-Q2
2025-06-25 N/A Årsstämma
2025-06-10 06:00 Kvartalsrapport 2025-Q1
2025-03-05 06:00 Bokslutskommuniké 2024
2024-12-20 - Extra Bolagsstämma 2024
2024-11-27 - Kvartalsrapport 2024-Q3
2024-09-12 - Kvartalsrapport 2024-Q2
2024-06-28 - Kvartalsrapport 2024-Q1
2024-06-27 - X-dag ordinarie utdelning SOFTX 0.00 NOK
2024-06-26 - Årsstämma
2024-03-20 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-09-26 - Kvartalsrapport 2023-Q2
2023-06-21 - Årsstämma
2023-06-21 - Kvartalsrapport 2023-Q1
2023-03-30 - X-dag ordinarie utdelning SOFTX 0.00 NOK
2023-02-17 - Bokslutskommuniké 2022
2022-12-09 - Extra Bolagsstämma 2022
2022-10-26 - Kvartalsrapport 2022-Q3
2022-08-15 - Kvartalsrapport 2022-Q2
2022-04-28 - Kvartalsrapport 2022-Q1
2022-04-19 - X-dag ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 - Årsstämma
2022-02-16 - Bokslutskommuniké 2021
2021-12-29 - Extra Bolagsstämma 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-09-08 - Kvartalsrapport 2021-Q2
2021-04-29 - Kvartalsrapport 2021-Q1
2021-04-14 - X-dag ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 - Årsstämma
2021-02-09 - Bokslutskommuniké 2020
2020-12-14 - Kvartalsrapport 2020-Q3
2020-09-30 - Kvartalsrapport 2020-Q2
2020-07-01 - X-dag ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 - Årsstämma
2020-06-30 - Kvartalsrapport 2020-Q1
2019-12-20 - Extra Bolagsstämma 2019
2019-06-27 - Årsstämma
2019-06-03 - X-dag ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 - Split SOFTX 1:50

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo, Norge.
2021-03-03 08:00:00
Reference is made to the stock exchange announcement from SoftOx Solutions AS
(the "Company") on 16 February 2021 regarding the commencement of the
subscription period in the subsequent offering of up to 181,818 new shares at a
subscription price of NOK 55 per offer share directed towards eligible
shareholders as of 16 December 2020 (as registered in the VPS on 18 December
2020) who did not participate in the private placement successfully completed
on the 16 December 2020 (the "Subsequent Offering").

The subscription period for the Subsequent Offering will expire today, on 3
March 2021 at 16:30 (CEST). In order to subscribe for offer shares, SpareBank 1
Markets AS (the "Manager") must receive a complete and duly signed subscription
form within 16:30 today.

Subscription rights that are not used to subscribe for offer shares before the
expiry of the subscription period will have no value and will lapse without
compensation to the holder.

For further information, please refer to the national prospectus available on
the Company's website www.soft-ox.com, the Manager's website www.sb1markets.no
and that may be ordered from the Norwegian Register of Business Enterprises (Nw:
Foretaksregisteret).

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, FM of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
MedTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com